Skip to main content
Home
Browse topics
Cardiovascular disorders Chronic kidney disease Diabetes devices & technology GLP-1 receptor agonists Hyperglycemia Hypoglycemia Obesity, diet, & lifestyle interventions SGLT2 inhibitors Type 1 diabetes Type 2 diabetes Browse all topics
EN
EN
In focus
Novel clinical evidence in continuous glucose monitoring Fasting for religion and health in people with diabetes The challenge of type 2 diabetes in children HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved Addressing suicide risk in diabetes: Rates and risk factors, HCP fears, and practical advice The SURPASS trials: Summarizing efficacy data on tirzepatide Semaglutide for weight loss: STEP and SELECT trials: Results from the STEP and SELECT trials Why psychosocial care matters DiRECT: Type 2 diabetes remission through weight management
Congress coverage
EASD 58th Annual Meeting 2022 The American Diabetes Association 82nd Scientific Sessions
About us
Medicine Matters Diabetes
EXTENDED SEARCH

Glucagon-like peptide-1 (GLP-1) receptor agonists

Journal articles and book chapters

15-06-2018 | Semaglutide | Article

Semaglutide s.c. once-weekly in type 2 diabetes: A population pharmacokinetic analysis

Carlsson Petri KC et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0458-5

14-06-2018 | Dulaglutide | Article

Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): A multicenter, open-label, randomized trial

Tuttle KR et al. Lancet Diabetes Endocrinol 2018. doi: 10.1016/S2213-8587(18)30104-9

13-06-2018 | Oral combination medications | Article

A randomized controlled trial of dapagliflozin plus once-weekly exenatide versus placebo in individuals with obesity and without diabetes: Metabolic effects and markers associated with bodyweight loss

Pereira MJ et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0449-6

05-06-2018 | Cardiovascular outcomes | Review | Article

Comparative cardiovascular outcomes in the era of novel anti-diabetic agents: A comprehensive network meta-analysis of 166,371 participants from 170 randomized controlled trials

Zhuang X et al. Cardiovasc Diabetol 2018; 17: 79. doi: 10.1186/s12933-018-0722-z

19-05-2018 | Liraglutide (T2DM) | Article

Retrospective analysis of an insulin-to-liraglutide switch in patients with type 2 diabetes mellitus

Introduction: Insulin and the GLP-1 receptor agonist liraglutide are both effective in reaching glycemic targets. The efficacy of an insulin-to-liraglutide switch in an obese population with concurrent use of sulfonylurea and metformin is unknown. We assessed the efficacy and determinants of success of an insulin-to-liraglutide switch in these patients.

09-05-2018 | Liraglutide (T2DM) | Article

Real-world clinical effectiveness and cost savings of liraglutide versus sitagliptin in treating type 2 diabetes for 1 and 2 years

Li Q et al. Diabetes Ther 2018; Advance online publication. doi: 10.1007/s13300-018-0432-2

04-05-2018 | SGLT2 inhibitors | Review | Article

Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes

Zheng et al. JAMA 2018; 319:1580. doi: 10.1001/jama.2018.3024

04-05-2018 | GLP-1 agonists | Review | Article

Glucagon-like peptide 1 in health and disease

Andersen A et al. Nat Rev Endocrinol 2018; Advance online publication. doi: 10.1038/s41574-018-0016-2

30-04-2018 | Semaglutide | Article

A systematic literature review and network meta-analysis comparing once-weekly semaglutide with other GLP-1 receptor agonists in patients with type 2 diabetes previously receiving basal insulin

Witkowski M et al. Diabetes Ther 2018; Advance online publication. doi: 10.1007/s13300-018-0428-y

19-04-2018 | Type 2 diabetes | Article

Treatment intensification in type 2 diabetes: A real-world study of 2-OAD regimens, GLP-1 RAs, or basal insulin

Blonde L et al. Diabetes Ther 2018; Advance online publication. doi: 10.1007/s13300-018-0429-x

05-04-2018 | Oral combination medications | Review | Article

Combination treatment of SGLT2 inhibitors and GLP-1 receptor agonists: Symbiotic effects on metabolism and cardiorenal risk

Goncalves E, Bell DSH. Diabetes Ther 2018; 9: 919–926. doi: 10.1007/s13300-018-0420-6

24-03-2018 | Insulin | Review | Article

Basal insulin intensification in patients with type 2 diabetes: A review

Meece J. Diabetes Ther 2018; Advance online publication. doi: 10.1007/s13300-018-0395-3

24-03-2018 | GLP-1 agonists | Review | Article

Use of glucagon‐like peptide‐1 receptor agonists among individuals on basal insulin requiring treatment intensification

Trautmann ME, Vora J. Diabet Med 2018; Advance online publication. doi: 10.1111/dme.13610

24-03-2018 | Semaglutide | Article

A network meta-analysis comparing semaglutide once-weekly with other GLP-1 receptor agonists in Japanese patients with type 2 diabetes

Webb N et al. Diabetes Ther 2018; Advance online publication. doi: 10.1007/s13300-018-0397-1

06-02-2018 | Post-transplant diabetes mellitus | Review | Article

Post-liver transplantation diabetes mellitus: A review of relevance and approach to treatment

Peláez-Jaramillo MJ et al. Diabetes Ther 2018; Advance online publication. doi: 10.1007/s13300-018-0374-8

03-02-2018 | Exenatide | Article

Changes in heart rate associated with exenatide once weekly: Pooled analysis of clinical data in patients with type 2 diabetes

Marso SP et al. Diabetes Ther 2018; Advance online publication. doi: 10.1007/s13300-018-0370-z

25-01-2018 | Heart failure | Review | Article

Effect of glucose-lowering therapies on heart failure

Nat Rev Cardiol 2018; Advance online publication. doi: 10.1038/nrcardio.2017.211

09-01-2018 | Exenatide | Article

Glucose control and weight change associated with treatment with exenatide compared with basal insulin: A retrospective study

Morgan CL et al. Diabetes Ther 2018; 9: 269–283. doi: 10.1007/s13300-017-0359-z

05-01-2018 | Cardiovascular outcomes | Review | Article

Pharmacological prevention of cardiovascular outcomes in diabetes mellitus: Established and emerging agents

Saxon DR, Rasouli N, Eckel RH. Drugs 2018; 78: 203–214. doi: 10.1007/s40265-017-0857-3

02-11-2017 | Heart failure | Review | Article

Treating disease mechanisms in patients with heart failure and diabetes mellitus

Trang A, Aguilar D. Curr Heart Fail Rep 2017; 14: 445–453. doi: 10.1007/s11897-017-0371-7

Next Previous